BioCryst Pharmaceuticals Inc
BCRX8.345USD
+0.395+4.97%
시장 운영 시간 （ET）시세는 15분 지연됩니다
1.75B시가총액
손실P/E TTM
자세한 내용은 BioCryst Pharmaceuticals Inc 회사
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
회사 정보
종목 코드 BCRX
회사 이름BioCryst Pharmaceuticals Inc
상장일Mar 04, 1994
CEOMr. Charles K. Gayer
직원 수580
유형Ordinary Share
회계 연도 종료Mar 04
주소4505 Emperor Blvd Ste 200
도시DURHAM
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호27703-8457
전화19198591302
웹사이트https://www.biocryst.com/
종목 코드 BCRX
상장일Mar 04, 1994
CEOMr. Charles K. Gayer
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
89.76K
+16.18%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
40.33K
+44.91%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Jul 12
마지막 업데이트: Sat, Jul 12
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
주주
주주
비율
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
주주 유형
주주
비율
Investment Advisor
32.45%
Investment Advisor/Hedge Fund
29.96%
Hedge Fund
18.97%
Research Firm
3.20%
Private Equity
1.84%
Individual Investor
1.27%
Pension Fund
0.53%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.25%
Other
11.14%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
549
185.97M
88.87%
-12.50M
2025Q1
560
182.40M
87.18%
-20.97M
2024Q4
556
172.66M
82.64%
-37.08M
2024Q3
554
179.19M
86.60%
-34.24M
2024Q2
532
180.82M
87.59%
-35.90M
2024Q1
546
187.78M
91.10%
-27.21M
2023Q4
549
183.67M
89.35%
-28.91M
2023Q3
542
183.90M
96.89%
-26.67M
2023Q2
545
181.25M
95.65%
-20.15M
2023Q1
554
177.87M
94.17%
-5.12M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
21.61M
10.33%
-230.66K
-1.06%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.89M
8.55%
+189.84K
+1.07%
Mar 31, 2025
Kynam Capital Management LP
8.93M
4.27%
-156.84K
-1.73%
Mar 31, 2025
Avoro Capital Advisors LLC
8.70M
4.16%
-3.17M
-26.68%
Mar 31, 2025
State Street Global Advisors (US)
7.81M
3.73%
+314.44K
+4.19%
Mar 31, 2025
Alkeon Capital Management LLC
6.00M
2.87%
+109.73K
+1.86%
Mar 31, 2025
Two Sigma Investments, LP
5.27M
2.52%
+992.22K
+23.22%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
2.48%
-2.95M
-36.28%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.96M
2.37%
+136.90K
+2.84%
Mar 31, 2025
RP Management, LLC
3.85M
1.84%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Genomics Immunology and Healthcare ETF
3.3%
Invesco Biotechnology & Genome ETF
2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
1.83%
Virtus LifeSci Biotech Products ETF
1.66%
ALPS Medical Breakthroughs ETF
1.27%
SPDR S&P Biotech ETF
0.68%
First Trust Small Cap Growth AlphaDEX Fund
0.66%
Main Thematic Innovation ETF
0.58%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
Invesco NASDAQ Future Gen 200 ETF
0.38%
더 보기
iShares Genomics Immunology and Healthcare ETF
비율3.3%
Invesco Biotechnology & Genome ETF
비율2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
비율1.83%
Virtus LifeSci Biotech Products ETF
비율1.66%
ALPS Medical Breakthroughs ETF
비율1.27%
SPDR S&P Biotech ETF
비율0.68%
First Trust Small Cap Growth AlphaDEX Fund
비율0.66%
Main Thematic Innovation ETF
비율0.58%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.39%
Invesco NASDAQ Future Gen 200 ETF
비율0.38%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
